SAN FRANCISCO, Jan. 14, 2020 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) issued a statement today following a meeting of the Food and Drug Administration's (FDA's) Anesthetic and Analgesic Drug Products…Original Article
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
